HC Wainwright Comments on Alumis’ Q3 Earnings (NASDAQ:ALMS)

Alumis Inc. (NASDAQ:ALMS) – Stock analysts at HC Wainwright cut their Q3 2025 earnings per share (EPS) estimates for shares of Alumis in a research report issued to clients and investors on Thursday, August 14th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($0.80) per share for the quarter, down from their previous forecast of ($0.74). HC Wainwright has a “Buy” rating and a $14.00 price target on the stock. The consensus estimate for Alumis’ current full-year earnings is ($8.51) per share. HC Wainwright also issued estimates for Alumis’ Q4 2025 earnings at ($0.79) EPS, FY2025 earnings at ($4.34) EPS, Q1 2026 earnings at ($0.81) EPS, Q2 2026 earnings at ($0.82) EPS, Q3 2026 earnings at ($0.90) EPS, Q4 2026 earnings at ($0.96) EPS and FY2026 earnings at ($3.49) EPS.

ALMS has been the topic of a number of other reports. Morgan Stanley reduced their price target on shares of Alumis from $23.00 to $22.00 and set an “overweight” rating on the stock in a research note on Friday. Oppenheimer dropped their price objective on shares of Alumis from $26.00 to $25.00 and set an “outperform” rating for the company in a research note on Thursday, May 15th. Wells Fargo & Company assumed coverage on shares of Alumis in a research report on Friday, July 25th. They issued an “overweight” rating and a $17.00 target price on the stock. Wall Street Zen upgraded shares of Alumis from a “strong sell” rating to a “hold” rating in a report on Saturday. Finally, Guggenheim upgraded Alumis to a “buy” rating and set a $18.00 price target for the company in a research note on Tuesday, June 10th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $20.17.

Alumis Stock Performance

Shares of NASDAQ ALMS opened at $4.75 on Monday. The stock’s fifty day moving average is $3.59 and its 200 day moving average is $4.65. Alumis has a 52 week low of $2.76 and a 52 week high of $13.11.

Alumis (NASDAQ:ALMS) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of ($1.11) by ($0.06). The business had revenue of $2.67 million during the quarter, compared to analysts’ expectations of $1.80 million.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ALMS. Rhumbline Advisers boosted its position in Alumis by 21.7% during the first quarter. Rhumbline Advisers now owns 16,543 shares of the company’s stock valued at $102,000 after acquiring an additional 2,949 shares during the last quarter. Corebridge Financial Inc. boosted its position in shares of Alumis by 53.0% during the first quarter. Corebridge Financial Inc. now owns 10,658 shares of the company’s stock valued at $65,000 after buying an additional 3,693 shares during the last quarter. Wells Fargo & Company MN grew its stake in shares of Alumis by 77.1% in the 4th quarter. Wells Fargo & Company MN now owns 8,779 shares of the company’s stock worth $69,000 after acquiring an additional 3,823 shares in the last quarter. Northern Trust Corp grew its position in Alumis by 4.3% in the 4th quarter. Northern Trust Corp now owns 111,326 shares of the company’s stock worth $875,000 after purchasing an additional 4,587 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Alumis by 64.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,535 shares of the company’s stock valued at $77,000 after acquiring an additional 4,926 shares during the last quarter.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.